ArticleBMJ open2020

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.

Alberto Bongiovanni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.